Cerium Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) for Corticotropin (ACTH) porcine (synthetic), otherwise referred to as SNP-ACTH (1-39) Gel. This investigational agent is in development for the treatment of primary membranous nephropathy (PMN) a rare kidney disease that affects approximately

Cerium Pharmaceuticals, Inc., a clinical stage biopharmaceuticals company focused on developing medicines for rare and orphan diseases, today announced that it has closed a $12 million Series B financing.